PMC:7172841 / 21911-22321 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T125","span":{"begin":18,"end":21},"obj":"Body_part"},{"id":"T126","span":{"begin":33,"end":42},"obj":"Body_part"},{"id":"T127","span":{"begin":78,"end":84},"obj":"Body_part"},{"id":"T128","span":{"begin":136,"end":142},"obj":"Body_part"},{"id":"T129","span":{"begin":328,"end":331},"obj":"Body_part"},{"id":"T130","span":{"begin":338,"end":347},"obj":"Body_part"}],"attributes":[{"id":"A125","pred":"fma_id","subj":"T125","obj":"http://purl.org/sig/ont/fma/fma84795"},{"id":"A126","pred":"fma_id","subj":"T126","obj":"http://purl.org/sig/ont/fma/fma62864"},{"id":"A127","pred":"fma_id","subj":"T127","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A128","pred":"fma_id","subj":"T128","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A129","pred":"fma_id","subj":"T129","obj":"http://purl.org/sig/ont/fma/fma84795"},{"id":"A130","pred":"fma_id","subj":"T130","obj":"http://purl.org/sig/ont/fma/fma62864"}],"text":"The expression of HLA-DR on CD14 monocytes was strongly inhibited by COVID-19 plasma from patients with immune dysregulation but not by plasma from patients with an intermediate immune state of activation (Figures 5C–5F); the addition of the specific blocker of the IL-6 pathway Tocilizumab partially restored the expression of HLA-DR on monocytes of all patients with immune dysregulation (Figures 5E and 5F)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T205","span":{"begin":69,"end":77},"obj":"Disease"}],"attributes":[{"id":"A205","pred":"mondo_id","subj":"T205","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"The expression of HLA-DR on CD14 monocytes was strongly inhibited by COVID-19 plasma from patients with immune dysregulation but not by plasma from patients with an intermediate immune state of activation (Figures 5C–5F); the addition of the specific blocker of the IL-6 pathway Tocilizumab partially restored the expression of HLA-DR on monocytes of all patients with immune dysregulation (Figures 5E and 5F)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T191","span":{"begin":33,"end":42},"obj":"http://purl.obolibrary.org/obo/CL_0000576"},{"id":"T192","span":{"begin":78,"end":84},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T193","span":{"begin":136,"end":142},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T194","span":{"begin":194,"end":204},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T195","span":{"begin":338,"end":347},"obj":"http://purl.obolibrary.org/obo/CL_0000576"}],"text":"The expression of HLA-DR on CD14 monocytes was strongly inhibited by COVID-19 plasma from patients with immune dysregulation but not by plasma from patients with an intermediate immune state of activation (Figures 5C–5F); the addition of the specific blocker of the IL-6 pathway Tocilizumab partially restored the expression of HLA-DR on monocytes of all patients with immune dysregulation (Figures 5E and 5F)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T121","span":{"begin":22,"end":24},"obj":"Chemical"},{"id":"T122","span":{"begin":266,"end":268},"obj":"Chemical"},{"id":"T124","span":{"begin":332,"end":334},"obj":"Chemical"}],"attributes":[{"id":"A121","pred":"chebi_id","subj":"T121","obj":"http://purl.obolibrary.org/obo/CHEBI_73445"},{"id":"A122","pred":"chebi_id","subj":"T122","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A123","pred":"chebi_id","subj":"T122","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A124","pred":"chebi_id","subj":"T124","obj":"http://purl.obolibrary.org/obo/CHEBI_73445"}],"text":"The expression of HLA-DR on CD14 monocytes was strongly inhibited by COVID-19 plasma from patients with immune dysregulation but not by plasma from patients with an intermediate immune state of activation (Figures 5C–5F); the addition of the specific blocker of the IL-6 pathway Tocilizumab partially restored the expression of HLA-DR on monocytes of all patients with immune dysregulation (Figures 5E and 5F)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T164","span":{"begin":0,"end":410},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The expression of HLA-DR on CD14 monocytes was strongly inhibited by COVID-19 plasma from patients with immune dysregulation but not by plasma from patients with an intermediate immune state of activation (Figures 5C–5F); the addition of the specific blocker of the IL-6 pathway Tocilizumab partially restored the expression of HLA-DR on monocytes of all patients with immune dysregulation (Figures 5E and 5F)."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T80","span":{"begin":104,"end":124},"obj":"Phenotype"},{"id":"T81","span":{"begin":369,"end":389},"obj":"Phenotype"}],"attributes":[{"id":"A80","pred":"hp_id","subj":"T80","obj":"http://purl.obolibrary.org/obo/HP_0002958"},{"id":"A81","pred":"hp_id","subj":"T81","obj":"http://purl.obolibrary.org/obo/HP_0002958"}],"text":"The expression of HLA-DR on CD14 monocytes was strongly inhibited by COVID-19 plasma from patients with immune dysregulation but not by plasma from patients with an intermediate immune state of activation (Figures 5C–5F); the addition of the specific blocker of the IL-6 pathway Tocilizumab partially restored the expression of HLA-DR on monocytes of all patients with immune dysregulation (Figures 5E and 5F)."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T647","span":{"begin":4,"end":14},"obj":"GO:0010467"},{"id":"T648","span":{"begin":18,"end":21},"obj":"PR:000029150"},{"id":"T649","span":{"begin":28,"end":32},"obj":"PR:000001889"},{"id":"T650","span":{"begin":33,"end":42},"obj":"CL:0000576"},{"id":"T651","span":{"begin":69,"end":77},"obj":"SP_7"},{"id":"T652","span":{"begin":78,"end":84},"obj":"UBERON:0001969"},{"id":"T653","span":{"begin":104,"end":110},"obj":"UBERON:0002405"},{"id":"T654","span":{"begin":111,"end":124},"obj":"GO:0065007"},{"id":"T655","span":{"begin":136,"end":142},"obj":"UBERON:0001969"},{"id":"T656","span":{"begin":178,"end":184},"obj":"UBERON:0002405"},{"id":"T657","span":{"begin":266,"end":270},"obj":"PR:000001393"},{"id":"T658","span":{"begin":279,"end":290},"obj":"DG_35"},{"id":"T659","span":{"begin":314,"end":324},"obj":"GO:0010467"},{"id":"T660","span":{"begin":328,"end":331},"obj":"PR:000029150"},{"id":"T661","span":{"begin":338,"end":347},"obj":"CL:0000576"},{"id":"T662","span":{"begin":369,"end":375},"obj":"UBERON:0002405"},{"id":"T663","span":{"begin":376,"end":389},"obj":"GO:0065007"},{"id":"T78000","span":{"begin":39,"end":45},"obj":"UBERON:0001969"},{"id":"T62942","span":{"begin":47,"end":57},"obj":"GO:0065007"},{"id":"T73958","span":{"begin":90,"end":94},"obj":"PR:000001393"},{"id":"T4451","span":{"begin":103,"end":115},"obj":"DG_35"},{"id":"T60524","span":{"begin":156,"end":159},"obj":"PR:000029150"},{"id":"T50596","span":{"begin":166,"end":170},"obj":"PR:000001889"},{"id":"T33458","span":{"begin":171,"end":180},"obj":"CL:0000576"},{"id":"T7540","span":{"begin":212,"end":222},"obj":"SP_7"},{"id":"T18315","span":{"begin":228,"end":233},"obj":"UBERON:0002405"},{"id":"T79191","span":{"begin":234,"end":247},"obj":"GO:0065007"},{"id":"T30207","span":{"begin":287,"end":293},"obj":"UBERON:0001969"},{"id":"T4094","span":{"begin":295,"end":305},"obj":"GO:0065007"},{"id":"T92474","span":{"begin":338,"end":342},"obj":"PR:000001393"},{"id":"T42158","span":{"begin":351,"end":362},"obj":"DG_35"}],"text":"The expression of HLA-DR on CD14 monocytes was strongly inhibited by COVID-19 plasma from patients with immune dysregulation but not by plasma from patients with an intermediate immune state of activation (Figures 5C–5F); the addition of the specific blocker of the IL-6 pathway Tocilizumab partially restored the expression of HLA-DR on monocytes of all patients with immune dysregulation (Figures 5E and 5F)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"947","span":{"begin":28,"end":32},"obj":"Gene"},{"id":"948","span":{"begin":266,"end":270},"obj":"Gene"},{"id":"957","span":{"begin":90,"end":98},"obj":"Species"},{"id":"958","span":{"begin":148,"end":156},"obj":"Species"},{"id":"959","span":{"begin":355,"end":363},"obj":"Species"},{"id":"961","span":{"begin":279,"end":290},"obj":"Chemical"},{"id":"967","span":{"begin":69,"end":77},"obj":"Disease"}],"attributes":[{"id":"A947","pred":"tao:has_database_id","subj":"947","obj":"Gene:929"},{"id":"A948","pred":"tao:has_database_id","subj":"948","obj":"Gene:3569"},{"id":"A957","pred":"tao:has_database_id","subj":"957","obj":"Tax:9606"},{"id":"A958","pred":"tao:has_database_id","subj":"958","obj":"Tax:9606"},{"id":"A959","pred":"tao:has_database_id","subj":"959","obj":"Tax:9606"},{"id":"A961","pred":"tao:has_database_id","subj":"961","obj":"MESH:C502936"},{"id":"A967","pred":"tao:has_database_id","subj":"967","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The expression of HLA-DR on CD14 monocytes was strongly inhibited by COVID-19 plasma from patients with immune dysregulation but not by plasma from patients with an intermediate immune state of activation (Figures 5C–5F); the addition of the specific blocker of the IL-6 pathway Tocilizumab partially restored the expression of HLA-DR on monocytes of all patients with immune dysregulation (Figures 5E and 5F)."}